Looking ahead, Mylan remains on track to close the pending combination with Pfizer’s Upjohn Business in the second half of the year. The company reaffirmed its 2020 revenue outlook in the range of $11.5-12.5 billion, absorbing about $200 million of foreign exchange headwinds versus its previous expectations, and adjusted EBITDA of $3.2-3.9 billion, absorbing about $50 million of foreign exchange headwinds.
The company anticipates full-year adjusted free cash flow generation to be consistent with 2019 levels despite the COVID-19 pandemic. Mylan continues to target about $1 billion of debt repayment during 2020 and remains fully committed to its investment-grade credit rating.
ADVERTISEMENT
Take a look at our Healthcare articles here